Polyfunctional antibody signature defines protection in Andes hantavirus survival - Scorecard - MDSpire

Polyfunctional antibody signature defines protection in Andes hantavirus survival

  • By

  • Felipe Bravo

  • Tybbysay P. Salinas

  • Camila Kossack

  • Jorge T. Gonzalez

  • Israel Giacaman

  • Claudio Quevedo

  • Sebastián Fuller

  • Farides Saavedra

  • Claudio Aguilera-Pérez

  • Felipe Aguilera

  • Raúl Riquelme

  • María Luisa Rioseco

  • Mario Calvo

  • Raymond A. Alvarez

  • Juan Miguel Pascale

  • Blas Armién

  • Maritza Navarrete

  • Jose Luis Garrido

  • Maria Ines Barria

  • June 5, 2026

  • 0 min

Share

Clinical Scorecard: Antibody Functionality Profile Indicates Protective Mechanisms in Andes Hantavirus Survivors

At a Glance

CategoryDetail
Condition
Key MechanismsFc-mediated effector functions
Target PopulationAcute HCPS patients and survivors
Care SettingClinical and research settings

Key Highlights

  • Survivors exhibit elevated IgG and IgM responses against ANDV glycoproteins.
  • Fc-mediated effector functions are associated with protective immune responses.
  • Polyfunctional non-neutralizing IgG activities persist for years post-infection.
  • Fcγ receptor engagement is critical for antibody-mediated antiviral activity.

Guideline-Based Recommendations

Diagnosis

  • Serological profiling of antibody types and subtypes in HCPS patients.

Management

  • Supportive care for hospitalized patients; no specific antiviral treatments available.

Monitoring & Follow-up

  • Evaluate antibody responses and Fc-mediated functions in patients.

Risks

  • High mortality rates (~30–40%) associated with severe HCPS.

Patient & Prescribing Data

Individuals infected with Andes orthohantavirus (ANDV)

Focus on understanding humoral immune responses for future vaccine development.

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    Related Content